Biomimetic DDS for overcoming intractable lung diseases by activation of macrophage functions
| Project/Area Number |
25282146
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Nigata University of Phermacy and Applied Life Sciences |
|---|
Principal Investigator |
TERADA Hiroshi 新潟薬科大学, 公私立大学の部局等, 教授 (00035544)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAKINO Kimiko 東京理科大学, 薬学部, 教授 (40147509)
HIROTA Keiji 東京理科大学, 薬学部, 助教 (50516359)
TAKEUCHI Issei 東京理科大学, 薬学部, 助教 (10734931)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
|
|---|
| Keywords | ドラッグデリバリーシステム / 結核 / 肺がん / 慢性閉塞性肺疾患 / マクロファージ / 経気管投与 / 薬物送達システム / COPD |
|---|
| Outline of Final Research Achievements |
In order to overcome intractable lung diseases, such as lung cancer and lung tuberculosis, it is highly efficient to deliver their therapeutic agents directly to the lesion sites by intratracheal insufflation. The nanocomposite particles (mean particle size: 7.8μm) consisting of PLGA (poly(lactic-co-glycolic) acid) nanoparticles (mean sizes: 190 nm) containing the antitubercular agent rifampicin were prepared. These particles were distributed homogeneously in the rat and mouse lungs by the intratracheal administration by the newly developed Venturi insufflator, showing efficient antitubercular effects. In addition, the antitumor agent cyclophosphamide (CPA) increased the population of the M1 lung macrophages located around the tumor cells and showed effective antitumor activity. The lipid A analog ONO-4007 enhanced these effects of CPA.
|
Report
(4 results)
Research Products
(28 results)
-
-
[Journal Article] Polyphosphoester-based Paclitaxel Complexes: Biological Evaluation2016
Author(s)
Keiji Hirota, Tatyana Hristova, Violeta Mitova, Tomoyuki Koda, Masahiro Fushimi, Mika Kuniya, Kimiko Makino, Hiroshi Terada, Rumyana Cherkezova, Shin-Ichi Yusa, Neli Koseva and Kolio Troev
-
Journal Title
Anticancer Res.
Volume: 36
Pages: 1613-1620
Related Report
Peer Reviewed
-
-
-
[Journal Article] A Novel Mechanism Underlying the Basic Defensive Response of Macrophages against Mycobacterium Infection.2014
Author(s)
Iyoda T, Takada M, Fukatsu Y, Kumokoshi S, Fujisawa T, Shimada T, Shimokawa N, Matsunaga T, Makino K, Doi N, Terada H, Fukai F
-
Journal Title
Journal of Immunology
Volume: 192（9）
Pages: 4254-4262
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] The behavior of PLGA microspheres containing rifampicin in alveolar macrophages
Author(s)
Onoshita, T., Fujiwara, N., Haga, M., Nakajima, T., Tomoda, K., Hirota, K., Terada, H., Makino, K.
Organizer
Inhaled Therapies for TB: Second Meeting--Tokyo2013
Place of Presentation
Tokyo, Morito Hall, TUS
Related Report
-
-
-
-
-
-
-
